For Doctors in a Hurry
- Despite opioid use disorder affecting 9,367,000 US adults in 2022, only 25.1 percent received approved medications to reduce unregulated use.
- This review analyzed pharmacological interventions for opioid use disorder, withdrawal, and overdose among the US adult population.
- Prescribing medications for opioid use disorder significantly reduced all-cause mortality, demonstrating an adjusted hazard ratio of 0.52 (95% CI, 0.42-0.63).
- The authors conclude that all patients with opioid use disorder must be offered methadone or buprenorphine to decrease all-cause mortality.
- Physicians should prescribe opioid agonists for withdrawal and ensure community access to naloxone, which lowers overdose rates by 25 to 46 percent.
The Persistent Treatment Gap in Opioid Use Disorder
Opioid use disorder remains a dominant public health crisis, affecting an estimated 3.7% of US adults (9,367,000 individuals) in 2022 and causing 53,774 deaths in 2024 [1]. While opioid agonist therapies like methadone and buprenorphine are highly effective at reducing both all-cause and overdose mortality, patients face a particularly high risk of death immediately after treatment cessation [2]. To combat this, acute care settings have increasingly focused on initiating medications for opioid use disorder directly in the emergency department, a strategy shown to significantly improve short-term treatment engagement compared to brief interventions alone [3, 4]. Despite these proven interventions, systemic barriers and fragmented care models continue to limit patient access to sustained pharmacological support, with only 25.1% of affected individuals in the US receiving these life-saving medications in 2022. A newly published clinical review synthesizes the latest evidence on optimizing medications for opioid use disorder, withdrawal management, and overdose reversal to help clinicians close this critical treatment gap.
Core Pharmacotherapy: Navigating Maintenance Options
Clinical guidelines emphasize that all individuals with opioid use disorder should be offered treatment with medications for opioid use disorder to reduce unregulated opioid use. The clinical review reinforces that these medications significantly reduce both morbidity and mortality. Currently, methadone, buprenorphine, and naltrexone are the primary medications approved by the US Food and Drug Administration to treat this condition. Among these pharmacological options, the opioid agonists (medications that activate opioid receptors to prevent withdrawal and cravings) provide the most robust survival benefits. The data show that methadone and buprenorphine reduce the risks of overdose and all-cause mortality, establishing them as essential interventions for long-term patient stabilization. To optimize adherence, treatment should be selected based on shared decision-making that considers the availability and convenience of options alongside patient preferences. Physicians must navigate distinct regulatory and logistical frameworks when initiating these therapies. Specifically, buprenorphine and naltrexone are prescribed in office-based settings and can be taken at home, which offers substantial flexibility for patients managing work or family responsibilities. In contrast, outpatients in the US can only obtain methadone in person at federally regulated clinics. Factoring in these structural differences is critical for clinicians aiming to match patients with a sustainable, accessible treatment plan that minimizes the risk of relapse.
Managing Acute Withdrawal to Prevent Mortality
After stopping or substantially reducing the use of opioids, individuals develop severe withdrawal symptoms, such as anxiety, insomnia, pain, nausea, vomiting, and diarrhea. Because these intense physiological responses frequently drive patients back to unregulated substance use, clinical management must address the immediate crisis. The review emphasizes that individuals benefit significantly from targeted medications to treat opioid withdrawal, providing a necessary bridge to long-term care. To stabilize patients during this vulnerable period, clinicians must utilize a multimodal pharmacological approach. The authors outline that withdrawal symptoms may be treated with opioid agonists, alpha-2-receptor agonists, and medications for pain and nausea. Specifically, first-line medications include opioid agonists (methadone and buprenorphine), which directly address the underlying receptor deficit and mitigate cravings. Adjunctive therapies are also critical to manage autonomic hyperactivity and physical discomfort. The review notes that clinicians should utilize alpha-2-receptor agonists (lofexidine and clonidine), which suppress sympathetic nervous system overactivity, alongside supportive medications to treat pain (ibuprofen) and nausea (ondansetron) for comprehensive symptomatic relief. However, managing acute symptoms is only the first step in clinical care, as detoxification alone leaves patients highly vulnerable to fatal overdose. The researchers stress that individuals being treated for acute withdrawal should also be prescribed long-term maintenance medications to decrease the risk of all-cause mortality (adjusted hazard ratio, 0.52; 95% CI, 0.42-0.63). Transitioning patients directly from acute withdrawal management to sustained therapy effectively halves their mortality risk, underscoring the absolute necessity of linking immediate stabilization to ongoing pharmacological support.
Overdose Reversal and Harm Reduction Strategies
Beyond managing withdrawal and maintaining long-term recovery, clinicians must be prepared to address acute, life-threatening crises. The clinical review notes that individuals who use unregulated substances may develop opioid overdose, which can cause respiratory depression, stupor, and, if severe, coma and death. When these emergencies occur, overdose can be rapidly reversed with naloxone, an FDA-approved opioid antagonist (a medication that tightly binds to opioid receptors to block and reverse the effects of other opioids). To avoid precipitating severe, sudden withdrawal symptoms while ensuring patient survival, the authors specify that naloxone should be administered at the lowest dose needed to restore a normal respiratory rate (0.4 mg intramuscularly or 2-4 mg intranasally). The impact of this intervention extends far beyond the emergency department or clinic setting. The researchers highlight that community-wide distribution of naloxone to people who use opioids and their social networks has been associated with 25% to 46% lower community opioid overdose rates. Because timely administration by bystanders is frequently the determining factor in survival, proactive prescribing is a critical component of comprehensive primary care. Consequently, the review concludes that all individuals with opioid use disorder should have access to opioid antagonists, such as naloxone, to treat overdose, ensuring that patients and their support systems are equipped to manage acute respiratory emergencies before emergency medical services arrive.
References
1. Beaulieu E, DiGennaro C, Stringfellow E, et al. Economic Evaluation in Opioid Modeling: Systematic Review.. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2021. doi:10.1016/j.jval.2020.07.013
2. Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017. doi:10.1136/bmj.j1550
3. Bavali-Gazik A, Hosseini SN, Salehian S, Kadkhoda M, Salari A, Akhavan-Abdollahian A. Emergency department-initiated buprenorphine vs brief intervention for opioid use disorder: a systematic review and meta-analysis of clinical trials.. Journal of Addictive Diseases. 2026. doi:10.1080/10550887.2025.2605451
4. Alabas MA, Alshahrani AA, Almobty SM, et al. Emergency Department-Initiated Buprenorphine for Opioid Use Disorder: A Systematic Review of Treatment Engagement and Emergency Care Utilization.. Cureus. 2026. doi:10.7759/cureus.101792
